



Client Services

Brentwood, TN: (800) 874-8532 fax: (615) 370-8074 Phoenix, AZ: (800) 710-1800 fax: (800) 481-4151 Shelton, CT: (800) 447-5816 fax: (212) 698-9532

Highlighted fields are REQUIRED

CLIENT INFORMATION			CLINICAL/SF	PECIMEN INFORMATION		
ORDERING	NPI#		Collection Date:	Time:	Fixative: 10% Neutral Buffered Formalin	
PHYSICIAN TREATING	NPI#		Body Site/Descriptor:		Other:	
PHYSICIAN	IVI III		Specimen ID#(s):	Characteristics (Add the Control Office III)	See Previous Case History	
Client#	<u> </u>		Paraffin Block(s) #:	☐ Choose best block (default) ☐ Stained Slides #: ☐ Perform tests on all blocks	Unstained Slides #: Other:	
			Diagnosis/Clinical Data			
Client Name			- Diagnosis/Olimoti Data	A.		
Address				e provided by the ordering physician or an auth toms in ICD-CM format in effect at Date of Serv		
			ICD-CM	ICD-CM	ICD-CM	
			BILLING INFO	ORMATION (face sheet & front and I	pack of insurance card must be attached)	
Phone Number						
Fax Number			Patient Hospital Stat	tus:	ent Non-Patient	
PATIENT INFORMATION			Insured Information:	Name		
Name (LAST, FIRST, MIDDLE):			Relationship to Patient (circle one) Self Spouse Child Other:			
Address:			Primary Insurance	Co:	Authorization #	
City, State, Zip:			Billing Address		Insured #	
Date of Birth: MM / DD / Y	YYY Sex: 🗆 r		Billing City, State, Zip	0	Group #	
Phone Number:	Jex. □1	″ Шг	Secondary Insurance	e Co: Group #	Insured #	
Med Rec # / Patient #:			DUVOIOLANIALIT	THORIZED CLONATURE		
	A LEVEL OF SERVICE (MU	IST CHOOSE		HORIZED SIGNATURE:	V DEDODT	
	•	31 CHOUSE			II REPORT	
☐ IHC stain - Technical Component only (slides) ☐ IHC Stain with Manual Interpretation ☐ IHC stain with Virtual Image - Technical Component only						
☐ A-ACT (Alpha-1-Antichymotrypsin)	□ CD30	☐ Factor XIIIa		LH (Luteinizing Hormone)	☐ Perforin	
☐ A-AT (Alpha-1-Antitrypsin) ☐ ACTH (Adrenocorticotropic Hormone)	□ CD31 □ CD33	☐ Fascin ☐ FLI-1		□ Lipase □ Lysozyme (Murimidase)	☐ PLAP (Placental Alkaline Phosphatase) ☐ PMS-2	
☐ Actin - Muscle Specific (HHF-35) ☐ Actin - Smooth Muscle (SMA)	□ CD34 □ CD35	☐ F0LR1 ☐ F0XP1		□ Mammaglobin □ MART-1①	☐ Pneumocystis carinii (PC) ☐ PR (Progesterone Receptor)	
☐ Adipophilin ☐ AE1/AE3 (pan-cytokeratin)	☐ CD43 ☐ CD45 (LCA, Leukocyte Common Antigen			□ MDM2 □ Melan-A	☐ PRAME ☐ Prolactin	
☐ AE1/AE3/PCK26 (pan-cytokeratin) ☐ AFP (Alpha Fetoprotein)	□ CD56 □ CD57	☐ Gastrin ☐ GATA-3		□ Melan-A/Ki-67 (Double Stain) □ Mesothelin	 □ PSA (Prostate Specific Antigen) □ PSAP (Prostatic Acid Phosphatase) 	
☐ ALK (D5F3 for NSCLC)① ☐ ALK-1	□ CD61 □ CD68	☐ GCDFP-15 ☐ GFAP (Glial Fibr	illan, Acidic Protoin)	□ MiTF □ MLH-1	☐ PSMA⊕ ☐ PTH (Parathyroid Hormone)	
☐ Amyloid A ☐ Androgen Receptor	□ CD71 □ CD79a	☐ Glucagon ☐ Glycophorin A		□ MOC-31 (Epithelial Related Antigen) □ MPO (Myeloperoxidase) □ MSH-2	☐ RCC (PNRA, Renal Cell Carcinoma) ☐ S100	
☐ Annexin A1	□ CD99	☐ Glypican-3		□ MSH-6	☐ SALL4	
☐ Arginase-1 ☐ B72.3 (TAG72)	☐ CD117 (c-KIT) ☐ CD123	☐ Granzyme B☐ Growth Hormor	ne (GH)	□ MUC1 □ MUC2	☐ Somatostatin (SOMA)☐ SOX10	
☐ BCL-1 (Cyclin D1) ☐ BCL-2	□ CD138 □ CD163	☐ HBME-1 (Huma ☐ HCG (Human Cl		☐ MUC4 ☐ MUC5AC	☐ SOX11 ☐ STAT6	
☐ BCL-2/BCL-6② ☐ BCL-6	□ CDK4 □ CDX-2	☐ Hemoglobin A ☐ HEP B CORE (H	. , ,	☐ MUM-1 (Multiple Myeloma Oncogene 1) ☐ MYO D1	☐ SATB2 ☐ Synaptophysin (Monoclonal)	
☐ Ber-EP4 (Epithelial Antigen)☐ Beta Amyloid	☐ CDX-2/CK-7④ ☐ CEA (Monoclonal)	☐ HEP B SURF (H☐ HEP PAR 1	BsAq) E	☐ Myogenin ☐ Myoglobin	☐ Synuclein② ☐ TAU	
☐ Beta-Catenin	☐ CEA (Polyclonal)	☐ HER2	ם astric IHC with equivocal ב	□ Myosin Heavy Chain (SMM-HC)	☐ TCL-1	
☐ BOB-1 ☐ BRAF V600E	☐ Chromogranin A ☐ Chymotrypsin			Neurofilament (NF) NKI-C3 (Melanoma Assoc. Antigen) NKX3 1	☐ TDT ☐ Thrombomodulin	
☐ CA 19.9 ☐ CA 125	☐ CK-5 ☐ CK-5/6	results (2+) will	he refleved to FISH	□ NKX3.1 □ NSE (Neuron Specific Enolase)	☐ Thyroglobulin ☐ TIA-1	
☐ CAIX (Carbonic Anhydrase IX) ☐ Calcitonin	☐ CK-7 ☐ CK-7/TTF-1④	☐ HGAL ☐ HHV8 (Herpes \	, - o	□ NSE (Neuron Specific Endase) □ 0CT-2 □ 0CT-3/4	☐ TLE1 ☐ TOXO (Toxoplasmosis)	
☐ Caldesmon ☐ Calponin	☐ CK-14 ☐ CK-17	☐ HLA-DŘ ☐ HMB-45		□ OSCAR②	☐ TRAP TriView Breast Triple Stain (CK-5/6, p63,	
☐ Calretinin ☐ CAM 5.2	☐ CK-18 ☐ CK-19	☐ HPL (Human PI ☐ HPV 6/11 by IS	acental Lactogen) 📗 🛭	□ p16 □ p40	CK-LMW) (Breast Microinvasion)@ Tech only	
☐ CAM 5.2/AE1	☐ CK-20	☐ HPV 16/18 by I	SH	□ p53 □ p57	☐ TriView Prostate Triple Stain	
□ CD1a □ CD2	☐ CK-HMW (34betaE12) ☐ CK-LMW (35betaH11)	 ☐ HPV 31/33 by II ☐ H. pylori (HBP) 	Ī	□ p63 □ p120	(P504S, p63, CK903) Tech only ☐ Trypsin	
☐ CD3 ☐ CD3/CD20②	☐ CMV (Cytomegalovirus)☐ c-MYC	☐ HSV I/HSV II (He		☐ Pan-Cytokeratin (AE1/AE3/PCK26)	 ☐ Tryptase M-Cell ☐ TSH (Thyroid Stimulating Hormone) 	
□ CD4 □ CD5	☐ COLL-IV (Type 4 Collagen) ☐ COX-2 (Cyclooxygenase 2)	□ IgD □ IgG		☐ Pan-Melanoma Cocktail (MART-1, Tyrosinase, HMB45)①	☐ TTF-1 (Thyroid Transcription Factor 1) ☐ Tyrosinase	
□ CD7 □ CD8	☐ D2-40 ☐ DBA44 (HCL)	☐ IgG4* ☐ IgM		☐ Parvovirus B19 ☐ PAX-2	☐ Ubiquitin☐ Uroplakin III	
□ CD10	☐ Desmin	☐ Inhibin		□ PAX-5 □ PAX-8	□ Villin	
□ CD14 □ CD15	□ DOG1 □ EBER by ISH	☐ INI-1 ☐ Insulin	[☐ PD-1 (Heme specimens only) ☐ PD-L1 22C3 KEYTRUDA® (semi-quant)	☐ Vimentin (VIM) ☐ VIP (Vasoactive Intestinal Polypeptide)	
☐ CD20 ☐ CD21	☐ E-Cadherin ☐ EMA (Epithelial Membrane Antigen)	☐ KAPPA☐ KAPPA by ISH		□ PD-L1 28-8 OPDIVO® (semi-quant) □ PD-L1 SP142 TECENTRIQ® (semi-quant)	☐ WT-1 (N-Terminus)	
□ CD22 □ CD23	☐ ER (Estrogen Receptor) ☐ ERG	☐ Ki-67 ☐ LAMBDA		☐ PDL-1 SP263 TECENTRIQ (semi-quant)		
□ CD25	☐ Factor VIII (vWF)	☐ LAMBDA by ISI	1	Other:		

Determining Necessity of Advance Beneficiary Notice of Non-coverage (ABN) Completion*

- 1. Diagnose. Determine your patient's diagnosis.
- 2. **Document.** Write the diagnosis code(s) on the front of this requisition.
- 3. **Verify.** Determine if the laboratory test(s) ordered for the patient is subject to Local Coverage Determination or National Coverage Determination. This information can be located in the policies published by your Medicare Administrative Contractor (MAC), CMS, or www.Labcorp.com/MedicareMedicalNecessity.
- 4. **Review.** If the diagnosis code for your patient **does not** meet the medical necessity requirements set forth by Medicare or the test(s) is being performed more frequently than Medicare allows, an ABN should be completed.
- *An ABN should be completed for all tests that are considered investigational (experimental or for research use) by Medicare.

How to Complete an Advance Beneficiary Notice of Non-coverage (ABN)

Medicare is very specific in requiring that all of the information included on the ABN be completed. Additionally, Labcorp requests that the specimen number or bar code label be included on the form. To be valid an ABN must:

- 1. Be executed on the CMS approved ABN form (CMS-R-131)
- 2. Identify the Medicare Part B Beneficiary, using the name as it appears on the patient's red, white and blue Medicare card
- 3. Indicate the test(s)/procedure(s) which may be denied within the relevant reason column
- 4. Include an estimated cost for the test(s)/procedure(s) subject to the ABN
- 5. Have 'Option 1', 'Option 2', or 'Option 3' designated by the beneficiary
- 6. Be signed and dated by the beneficiary or his/her representative prior to the service being rendered

ONC 679 IHC Rev. 03/09/2023